Search results for "CLO"

showing 10 items of 9986 documents

Renal Allograft Compartment Syndrome: Is It Possible to Prevent?

2016

Renal allograft compartment syndrome (RACS) is a complication characterized by increased pressure over 15 to 20 mm Hg of the iliac fossa site of transplanted kidney that can lead to a reduction of the blood supply to the graft, resulting in organ ischemia. This study aims to evaluate, through a review of the literature, the incidence, detection, treatment, and possible prevention of RACS. The incidence of this complication, which appears generally in the immediate post-transplantation period, is currently approximately 1% to 2% and is underestimated because of poor nosography for the presence of symptoms common to other post-transplantation complications. Doppler ultrasound is indispensable…

medicine.medical_specialtymedicine.medical_treatmentIschemiaIliac fossa030230 surgeryCompartment SyndromesAbdominal wall03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHumansCompartment (pharmacokinetics)Reduction (orthopedic surgery)Transplantationbusiness.industryIncidence (epidemiology)Abdominal Wound Closure Techniquesmedicine.diseaseDecompression SurgicalKidney TransplantationSurgery; TransplantationSurgerySettore MED/18 - Chirurgia Generalemedicine.anatomical_structureEarly Diagnosis030220 oncology & carcinogenesisRenal allograftSurgeryComplicationbusinessTransplantation proceedings
researchProduct

Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy

2020

Abstract Purpose To report a female patient of biclonal Lewis syndrome which consists of a trias: biclonal gammopathy of undetermined significance, paraproteinemic keratopathy in form of a brownish discoid opacification at the level of Descemet's membrane and hypercupremia. After several years there was a conversion to multiple myeloma. Systemic chemotherapy led to a complete remission of multiple myeloma and to a normalization of the copper level in the blood that lasted five years. The corneal opacification remained unchanged. Observations A currently 66-year-old woman suffered from biclonal Lewis syndrome. On both eyes there is a central discoid yellow-brownish discoloration in the Pre-D…

medicine.medical_specialtymedicine.medical_treatmentUnchanged corneal opacity after chemotherapyGastroenterology03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyChemotherapy-induced normal level of copper in serumInternal medicineMedicineAffinity of IgG to copper in Lewis syndromeCopper levelsProgressive anemiaMultiple myelomaLewis syndromeHypercupremiaChemotherapyBiclonal gammopathybusiness.industrySystemic chemotherapyHypercupremiaCorneal opacitymedicine.diseaseOphthalmologylcsh:RE1-994030221 ophthalmology & optometrybusinessDiscoid brownish opacification of Descemet membrane030217 neurology & neurosurgeryAmerican Journal of Ophthalmology Case Reports
researchProduct

Vaginal Reconstruction Using the Bladder and/or Rectal Walls in Patients with Radiation-Induced Fistulas

2000

Abstract Objective. In irreparable or recurrent vesicovaginal fistulas and cloacal defects following high-dose irradiation therapy for gynecological malignancies, urinary diversion is the last resort to achieve a socially acceptable solution. In a select group of young and tumor-free patients, additional vaginal reconstruction may be indicated. Multiple operative procedures are available, but the results are often disappointing in the previously irradiated area. Materials and methods. In six such patients with large radiogenic vesicovaginal defects ( n = 5) or a cloacal fistula ( n = 1), a continent reservoir using the transverse colon with an umbilical stoma was performed. At the end of th…

medicine.medical_specialtymedicine.medical_treatmentUrinary BladderUterine Cervical NeoplasmsUrinary DiversionVesicovaginal fistulaIntroitusCloacaStoma (medicine)medicineHumansRadiation InjuriesUrinary bladderVesicovaginal Fistulabusiness.industryUrinary diversionRectumColostomyObstetrics and GynecologyPlastic Surgery Proceduresmedicine.diseaseSurgerymedicine.anatomical_structureUrethraOncologyVaginaVaginaFemalebusinessGynecologic Oncology
researchProduct

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review.

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue.This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-relat…

medicine.medical_specialtymedicine.medical_treatmentmacromolecular substances030226 pharmacology & pharmacyDrug reaction with eosinophilia and systemic symptoms03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsAntipsychoticClozapineClozapinebusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseDermatologyHypersensitivity reactionnervous system030220 oncology & carcinogenesisDrug Hypersensitivity SyndromePolypharmacySchizophreniabusinessmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Our experience with prurigo nodularis treated with dupilumab.

2020

medicine.medical_specialtyprurigo nodularibusiness.industryPruritusMEDLINEDermatologyDupilumabmedicine.diseaseAntibodies Monoclonal HumanizedDupilumabDermatologyInfectious DiseasesMedicineHumansPrurigobusinessNeurodermatitisPrurigo nodularisNeurodermatitisJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Inhibition of the NF-κB Signaling Pathway Mediates the Anti-inflammatory Effects of Petrosaspongiolide M

2003

Petrosaspongiolide M (PT) is a potent secretory phospholipase A(2) inhibitor and anti-inflammatory agent. This marine metabolite reduced the production of nitrite, prostaglandin E(2), and tumor necrosis factor-alpha in the mouse air pouch injected with zymosan. These effects were also observed in mouse peritoneal macrophages stimulated with zymosan. Inhibition of these inflammatory mediators was related to reductions in inducible nitric oxide synthase, cyclo-oxygenase-2, and tumor necrosis factor-alpha expression. Since nuclear factor-kappaB (NF-kappaB) appears to play a central role in the transcriptional regulation of these proteins by macrophages, we investigated the effects of PT on thi…

medicine.medical_treatmentAnti-Inflammatory AgentsNitric Oxide Synthase Type IIBiochemistryDinoprostoneMicechemistry.chemical_compoundPhospholipase A2NF-KappaB Inhibitor alphaCell MovementmedicineAnimalsRNA MessengerOleanolic AcidPhosphorylationNitritesPharmacologybiologyTumor Necrosis Factor-alphaZymosanNF-kappa BZymosanBiological TransportNF-κBDNACell biologyIsoenzymesNitric oxide synthaseIκBαCytokinechemistryBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesModels AnimalMacrophages Peritonealbiology.proteinCytokinesI-kappa B ProteinsTumor necrosis factor alphaNitric Oxide SynthaseSignal TransductionProstaglandin E
researchProduct

Clinical implications ofCYP3Apolymorphisms

2006

Due to their enormous substrate spectrum CYP3A4, -3A5 and -3A7 constitute the most important drug-metabolising enzyme subfamily in humans. CYP3As are expressed predominantly, but not exclusively, in the liver and intestine, where they participate in the metabolism of 45 - 60% of currently used drugs and many other compounds such as steroids and carcinogens. CYP3A expression and activity vary interindividually due to a combination of genetic and nongenetic factors such as hormone and health status, and the impact of environmental stimuli. Over the past several years, genetic determinants have been identified for much of the variable expression of CYP3A5 and -3A7, but not for CYP3A4. Using th…

medicine.medical_treatmentBiologyToxicologyBioinformatics030226 pharmacology & pharmacyGene Expression Regulation EnzymologicTacrolimusVariable Expression03 medical and health sciencesProstate cancer0302 clinical medicinemedicineCytochrome P-450 CYP3AHumansCYP3A5PharmacologyRegulation of gene expressionGeneticsPolymorphism GeneticCYP3A4General Medicinemedicine.diseaseTacrolimus3. Good healthIsoenzymesImmunosuppressive drug030220 oncology & carcinogenesisCyclosporineImmunosuppressive AgentsPharmacogeneticsExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

A hyaluronic acid/cyclodextrin based injectable hydrogel for local doxorubicin delivery to solid tumors

2020

Localized delivery of anticancer drugs is often the most useful therapeutic approach for the treatment of solid tumors. The use of injectable polymeric systems that maximize drug concentration in the proximal area of the tumor represents an extremely advantageous therapeutic strategy. Here, the development of an injectable in situ forming hydrogel was accomplished by exploiting the azo-type Michael reaction between an amine derivative of hyaluronic and vinylsulfone functionalized -cyclodextrins complexing doxorubicin. This injectable system can be easily prepared and administered with timelines compatible with normal operating room procedures, as demonstrated by rheological tests. In vitro…

medicine.medical_treatmentPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAnimal modelIn vivoNeoplasmsHyaluronic acidmedicineAnimalsDoxorubicinHyaluronic Acidchemistry.chemical_classificationCyclodextrinsChemotherapyCyclodextrinChemistryHydrogels021001 nanoscience & nanotechnologyIn vitroDrug concentrationDoxorubicinLocalized chemotherapy hyaluronic acid cyclodextrins in situ forming hydrogel DoxorubicinSettore CHIM/09 - Farmaceutico Tecnologico Applicativo0210 nano-technologyBiomedical engineeringmedicine.drug
researchProduct